Aktiesnakken — November 2010
-
omsætningen i Gen er så lav at hvis de institutionelle pludseligt køber den nye strategi, så kan det nok blive interessant. Men den relative
-
værdiansættelse af genmab er attraktiv ift. peers. Også Zealand
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
